You are here
DXS INTERNATIONAL PLC
The Board of DXS International plc (the “Company”), the NEX quoted clinical decision support developer and supplier of clinical decision support systems is pleased to confirm that it has been notified that the CEO, David Immelman and Bob Sutcliffe, the Chairman, have purchased on 18th and 19th October a total of 120,538 Ordinary Shares at the following prices:
|Date of trade||Director||Number of Shares||Price per share|
|18th October||David Immelman||20,538||8.660p|
|19th October||Bob Sutcliffe||100,000||8.515p|
Following the transactions specified above Mr Immelman now holds 3,637,737 Ordinary Shares representing 10.34% of the issued share capital of the Company and Mr Sutcliffe holds 437,691 Ordinary Shares representing 0.96% of the issued share capital of the Company.
The Directors of DXS International plc accept responsibility for this announcement
|David Immelman (Chief Executive)|
DXS International plc
City & Merchant
|0207 101 7676|
|Level 17, Dashwood House|
69 Old Broad Street,
Note to Editors:
DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively which should significantly contribute towards the NHS achieving its projected efficiency savings.